Psoriasis Articles
Biological Therapy Interruption and Re-Treatment in Chronic Plaque Psoriasis
While biological treatments for chronic plaque psoriasis should be administered continuously to maximize and maintain efficacy, interruptions in therapy may be necessary for a number of reasons. We reviewed the evidence from clinical trials on efficacy, safety and immunogenicity in clinical trials for approved biologic agents for chronic plaque psoriasis. A systematic search of three major medical databases was performed and a total of 35 articles were included into the analysis, including 13 controlled trials. J Drugs Dermatol. 2021;20(10):1063-1071. doi:10.36849/JDD.5716 Read more.
A Retrospective Review of Patients’ Response to Biologic Therapy for Psoriasis
Jerry Bagel MD MS, Brianna Butler MS PA-C, Elise Nelson LPN CCRC, Alexa Hetzel MS PA-C
Biologic treatments have taken the forefront in treating moderate-to-severe psoriasis. Although numerous randomized, controlled trials have demonstrated the efficacy of these agents, there is limited data suggesting that clinical trial outcomes are reproducible in real-world patients. J Drugs Dermatol. 20(4):442-449. doi:10.36849/JDD.2021.5823 Read more.
Sponsored
Assessing the Risk of PDE4 Use for Psoriasis During the COVID-19 Pandemic
Donovan G. Kearns, Shelley Uppal PhD, Vipawee S. Chat, Jashin J. Wu MD
As the COVID-19 pandemic persists globally, physicians continue to assess the safety and benefit of immunomodulatory medications, in order to reduce the risk of infection or worsened disease outcomes in patients. While there is emerging evidence that targeted immunosuppression may be helpful in cases of severe COVID-19 infection with cytokine storm, this effect cannot be generalized to all immunomodulatory medications. J Drugs Dermatol. 2021;20(05):582
Once-Daily Novel Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants
Seemal R. Desai MD, Brad Glick DO MPH, James Q. Del Rosso DO, Susan Harris MS, Abby Jacobson MS PA-C
Psoriasis is a chronic, inflammatory disease that may differ in prevalence and clinical presentation among patients from various racial and ethnic groups. Two phase 3 studies demonstrated efficacy and safety of a novel 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis (NCT02514577, NCT02515097). These post hoc analyses evaluated HP 0.01% lotion in Hispanic participants. J Drugs Dermatol. 20(3):252-258. doi:10.36849/JDD.2021.5698
Podcast Episodes
What Women Don’t Want … Psoriasis
Picking up on Prescribing Patterns for Psoriasis: A Real Deal Assessment
We are fortunate to live during a time when we have many safe and effective options to treat a chronic inflammatory skin disease such as Psoriasis. How does clinical trial efficacy and long term use translate to the real world and practical issues such as access, patient and practitioner perception? In a JDD Podcast, two investigators share their work and first steps to evaluate.
To Treat or Not To Treat: Systemic Therapy Considerations for Psoriasis in the Setting of Malignancy
In most phase 3 studies patients are weeded out or the history of malignancy must be at least 5 years prior to entry. So what to do? Our colleagues at Tufts Medical Center asked this very question. Tune in to hear what Dr. David Rosmarin learned from performing a retrospective chart review and how his work and his experience guides his clinical decision making when managing psoriasis.
Ask the Investigator: Shedding Some Light on Phototherapy Protocols for Psoriasis and Tips to Improve Patient Screening and Treatment
Dr. Adam Friedman reviews phototherapy protocols and pearls with psoriasis expert Dr. Jashin Wu. Also tune in to hear how Dr. Wu counsels his psoriasis patients on psoriasis comorbidities and initiates, and manages them with phototherapy, topicals, and systemic immunosuppressants.
Translational Lecture Series
Targeting cAMP Signaling for the Treatment of Inflammatory Diseases of the Skin
Dr. Jon Zippin elucidates the complexity of cAMP biology and the translational impact of PDE4 inhibition as it relates to chronic inflammatory skin diseases. Tune in to learn why targeting this pathway is clinically meaningful but also where more work is needed to improve outcomes.
Psoriasis: Biological Basis for Comorbidities
Dr. Abrar Qureshi, Professor and Chair of Department of Dermatology at The Warren Alpert Medical School of Brown University, reviews his research to uncover the biological basis for many of the co-morbidities associated with, and risk factors for, psoriasis. Through this clear and clinically oriented presentation, the common pathophysiological threads are elucidated with a focus on identifying preventive strategies and therapeutic targets for current and future treatments.
Stay up-to-date on new clinical findings in Psoriasis.View the latest articles, case reports, supplements, podcast episodes and more!
